Skip to main content
. 2015 Jun 20;26(9):2347–2353. doi: 10.1007/s00198-015-3129-7

Table 3.

Relative risk reduction (RRR, %) between treatments (teriparatide versus placebo) for morphometric vertebral fractures at different values of 10-year probability of hip fracture calculated without BMD, assuming no treatment

Percentile FRAX 10-year probability, no treatment RRR
Estimate 95 % CI
10th 3.4 % 86 % 49–96 %
25th 4.9 % 85 % 52–95 %
50th 8.0 % 82 % 54–93 %
75th 12.1 % 77 % 49–90 %
90th 18.4 % 68 % 1–90 %